SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 9.99% Stake in Stoke Therapeutics
Beneficial Ownership Disclosure
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 9.99% in Stoke Therapeutics, Inc., totaling 5,310,033 shares as of December 31, 2024.
Summary
- RTW Investments, LP and Roderick Wong, M.D., collectively referred to as the "Reporting Persons," beneficially own 5,310,033 shares of Stoke Therapeutics, Inc. Common Stock.
- This ownership represents 9.99% of the company's outstanding shares.
- The calculation of the percentage is based on 52,966,977 shares outstanding as of October 31, 2024, as reported in Stoke Therapeutics' Form 10-Q filed on November 5, 2024.
- The reported amount includes the assumed exercise of 186,508 warrants held by the Reporting Persons.
- The terms of the warrants prevent the Reporting Persons from exercising them if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
- RTW Investments, LP acts as the investment adviser to certain funds (the "RTW Funds"), which directly hold the shares.
- Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW Investments.
- RTW Master Fund Ltd., an RTW Fund, has the right to receive dividends or proceeds from the sale of more than 5% of the Shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Risks
- The Reporting Persons are limited by warrant terms from exercising additional warrants if it would cause their beneficial ownership to exceed 9.99% of Stoke Therapeutics' outstanding shares.
Future Outlook
This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Stoke Therapeutics' business or financial performance.
Industry Context
This filing indicates a significant, continued investment by a specialized healthcare investment firm, RTW Investments, in Stoke Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector, where institutional investors often take substantial positions in companies with promising pipelines.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake can influence market perception, trading volume, and potentially the share price, signaling confidence or a strategic position by a major fund.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which 52,966,977 shares of Stoke Therapeutics were reported outstanding in the company's Form 10-Q. |
| 2024-11-05 | Date Stoke Therapeutics filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G statement (reporting period end date). |
| 2025-02-14 | Date this Schedule 13G Amendment No. 6 was signed and filed. |
Keywords
Stoke Therapeutics, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.